TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15993354
Drug: Standard glycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glycemic treatment
Study: 6348485
Drug: Opipramol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opipramol (50 mg sugar-coated tablets)
Study: 29487223
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus carboplatin, paclitaxel, and bevacizumab (Arm A)
Study: 29487223
Drug: Carboplatin, paclitaxel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin, paclitaxel, and bevacizumab without metformin (Arm B)
Study: 16537213
Drug: Combination device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination device involving radiofrequency, infrared light, and mechanical suction-based massage (20 watts RF, 20 watts IR, 200 millibar vacuum)
Study: 7945629
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intracervical PgE2 gel
Study: 2908030
Drug: CV 205-502
Normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CV 205-502 (0.05 to 0.15 mg once daily for 6 months)
Study: 31479717
Drug: WW +
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WW + Tyr (white wine plus 25 mg Tyr capsule)
Study: 23425772
Drug: ω-3 fatty
Normalized name: ω-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 fatty acids (1440 mg/day, n=8)
Study: 21035980
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg loading dose of warfarin
Study: 21035980
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg dose of warfarin
Study: 21035980
Drug: Enoxaparin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1.5 mg/kg per day)
Study: 9550501
Drug: Moderate lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate lipid-lowering therapy
Study: 3296159
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (5000 I.U. subcutaneous injection once a day for 5 consecutive weekdays)
Study: 3296159
Drug: Placebo (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous injection once a day for 5 consecutive weekdays)
Study: 31982480
Drug: Exenatide (Bydureon),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (Bydureon), 12 weeks treatment
Study: 29887321
Drug: New vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: New vaccines added to the early childhood vaccine schedule (4 new antigens); assessed from 2006 to 2016.
Study: 29887321
Drug: All vaccines
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All vaccines included in the schedule; assessed in 2016.
Study: 29887321
Drug: New vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: New vaccines introduced; assessed within 2 years of their introduction.
Study: 29887321
Drug: Incomplete vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incomplete vaccine status by 24 months of age; associated factors.
Study: 26573910
Drug: Rapid diagnostic
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid diagnostic tests (RDTs) for malaria introduced in registered drug shops
Study: 22047971
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ocrelizumab
Study: 22047971
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg ocrelizumab
Study: 19168445
Drug: Goserelin (gonadotrophin-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (gonadotrophin-releasing hormone analog) for 24 weeks
Study: 19168445
Drug: Bicalutamide (androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (androgen receptor blocker) for 24 weeks
Study: 16842666
Drug: enalapril +
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril + spironolactone (20 mg/d)
Study: 16842666
Drug: anti‐hypertensive drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti‐hypertensive drugs not directly affecting RAAS (group C)
Study: 11299036
Drug: Effervescent tablets
Normalized name: Hydralyte Effervescent Tablets Berry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent tablets of chloroquine phosphate 300 mg
Study: 11299036
Drug: Uncoated tablets
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uncoated tablets of chloroquine phosphate 300 mg
Study: 2758732
Drug: Intravenous nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nalbuphine (0.2 mg/kg) in children (group I)
Study: 2758732
Drug: Intravenous nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nalbuphine (10 mg) in healthy volunteers (group II)
Study: 2758732
Drug: Oral nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nalbuphine (30 mg) in healthy volunteers (group II)
Study: 2758732
Drug: Intravenous nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nalbuphine (10 mg) in elderly patients (group III)
Study: 2758732
Drug: Oral nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nalbuphine (30 mg) in elderly patients (group III)
Study: 9535664
Drug: Breakfast cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast cereal fortified with 127 microg of folic acid daily
Study: 9535664
Drug: Breakfast cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast cereal fortified with 499 microg of folic acid daily
Study: 9535664
Drug: Breakfast cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast cereal fortified with 665 microg of folic acid daily
Study: 30862635
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol with additional use of electrical impedance tomography (EIT)
Study: 30862635
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol without additional use of electrical impedance tomography (EIT)
Study: 27611433
Drug: Respiratory Physical
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory Physical Therapy (RPT)
Study: 21777974
Drug: 14-day standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day standard therapy (lansoprazole, amoxicillin, clarithromycin)
Study: 21777974
Drug: 5-day concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day concomitant therapy (lansoprazole, amoxicillin, clarithromycin, metronidazole)
Study: 22849546
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy (5 days of lansoprazole and amoxicillin followed by 5 days of lansoprazole, clarithromycin, and metronidazole)
Study: 15060437
Drug: GW433908 1395
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW433908 1395 mg QD + RTV 200 mg QD
Study: 15060437
Drug: GW433908 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW433908 700 mg BID + RTV 100 mg BID
Study: 15060437
Drug: GW433908 1395
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW433908 1395 mg QD + RTV 300 mg QD
Study: 15060437
Drug: EFV 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFV 600 mg QD with GW433908 + RTV regimen
Study: 15060437
Drug: EFV 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFV 600 mg QD with GW433908 1395 mg QD + RTV 200 mg QD
Study: 8834668
Drug: Low-dose antacids
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antacids (bismuth subnitrate - Gastrin and Wikalina)
Study: 2642979
Drug: Intravenous glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous glucagon (40 micrograms/min)
Study: 2642979
Drug: Intravenous vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous vasopressin (0.2 units/min)
Study: 1103919
Drug: Morphine (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (in animal experiments)
Study: 17456652
Drug: Dexamethasone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (all doses)
Study: 18356831
Drug: Tesofensine 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesofensine 0.125 mg
Study: 19824222
Drug: Tesofensine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesofensine 1.0 mg
Study: 18356831
Drug: Tesofensine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesofensine (all doses combined)
Study: 18356831
Drug: Tesofensine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesofensine (0.25 mg and above)
Study: 12900815
Drug: Oral heme
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral heme iron
Study: 8153036
Drug: Educational training
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational training program combining self-management training and cognitive behaviour therapy; ten 1-hour sessions over 18 months.
Study: 2869638
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsule of temazepam 20 mg
Study: 2869638
Drug: Tablet of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet of temazepam 20 mg
Study: 27339057
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with fractional Er:YAG laser and 5% amorolfine lacquer (group 1)
Study: 23156940
Drug: Rhythmic Movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythmic Movement Therapy (RMT)
Study: 18271231
Drug: Bezoxazocine injection,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezoxazocine injection, 20 mg once, three times per day
Study: 11991284
Drug: Low-dose local
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose local nasal immunotherapy (LNIT) with a build-up phase from 2.5 AU to 80 AU and maintenance at 80 AU once a week
Study: 10209659
Drug: Group psychological
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group psychological treatment (education, relaxation, breathing training, graded exposure to activity and exercise, challenging automatic thoughts about heart disease)
Study: 10209659
Drug: Group psychological
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group psychological treatment
Study: 8531509
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg DL-oxyfedrine*HCl tablets
Study: 8531509
Drug: 96 mg
Normalized name: camphor 96 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 96 mg DL-oxyfedrine*HCl tablets
Study: 8531509
Drug: Equimolar aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equimolar aqueous solution of DL-oxyfedrine*HCl
Study: 23471549
Drug: rFSH +
Normalized name: rFSH-alpha
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rFSH + letrozole (2.5 mg on days 3-7 of the menstrual cycle)
Study: 21029314
Drug: Intravesical chemotherapy
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical chemotherapy alone (mitomycin-C)
Study: 8375130
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg desipramine
Study: 8375130
Drug: 225 mg
Normalized name: tyrosine 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg fluvoxamine
Study: 8375130
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg moclobemide
Study: 3522157
Drug: Brodimoprim (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodimoprim (400 mg loading dose followed by 200 mg for 10 days)
Study: 3522157
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg loading dose followed by 100 mg for 10 days)
Study: 22203318
Drug: Mindfulness-oriented therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-oriented therapy
Study: 20691832
Drug: Pexelizumab treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexelizumab treatment
Study: 18294109
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg administered as a 2-minute intravenous bolus injection
Study: 18294109
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg administered as a 30-minute continuous infusion
Study: 18294109
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo) administered as an intravenous injection over 2 minutes
Study: 12626998
Drug: Prostacyclin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostacyclin (5 ng x kg(‐1) x min(‐1)) plus unfractionated heparin
Study: 12626998
Drug: Prostacyclin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostacyclin plus unfractionated heparin
Study: 11076347
Drug: Short-term topical
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term topical steroid therapy (6 months)
Study: 11076347
Drug: Long-term topical
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term topical steroid therapy (12 months)
Study: 11076347
Drug: Systemic and
Normalized name: Estradiol and Levonorgestrel Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic and local steroids treatment
Study: 3539033
Drug: Topical anaesthetic
Normalized name: Topical anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthetic cream
Study: 31759938
Drug: Evolocumab 140
Normalized name: evolocumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 140 mg every 2 weeks for 6 weeks
Study: 30920584
Drug: Prolonged bivalirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged bivalirudin infusion
Study: 25692612
Drug: Standard bivalirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bivalirudin treatment
Study: 16762754
Drug: Glucose-insulin-potassium (GIK)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium (GIK)
Study: 16762754
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine (LDD)
Study: 15245597
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of 9 capsules of green tea extract powder per day (equivalent to 10 cups of regular green tea) for 5 months
Study: 15245597
Drug: No intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intake of green tea capsules (control group)
Study: 11688594
Drug: Estradiol and
Normalized name: Estradiol and Norgestimate Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol and progesterone replacement therapy for 6 weeks postnatally
Study: 29713403
Drug: Gluteal trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluteal trigger point injections with prilocaine, home exercise program, and oral medications
Study: 29713403
Drug: Home exercise
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home exercise program and oral medications
Study: 27320846
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea polyphenols (GTP) containing 800 mg of epigallocatechin gallate
Study: 22650140
Drug: New percutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: New percutaneous absorption herbal patch
Study: 22650140
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (Accuhaler)
Study: 22650140
Drug: Medicine patch
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine patch and medicinal vesiculation groups
Study: 22650140
Drug: Medicine patch
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine patch group
Study: 10850304
Drug: Whole Tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Tumor (WT) vaccine
Study: 10850304
Drug: TC vaccine
Normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC vaccine (derived from IIB-MEL-J cells)
Study: 10850304
Drug: No immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No immunotherapy (control group)
Study: 30554748
Drug: CRP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP group A (threshold of 20 mg/L)
Study: 30554748
Drug: CRP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP group B (threshold of 40 mg/L)
Study: 30554748
Drug: CRP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP group A (CRP <20 mg/L)
Study: 30554748
Drug: CRP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP group B (CRP <40 mg/L)
Study: 30562293
Drug: Self-administered 3-item
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered 3-item questionnaire (3IQ)
Study: 22344554
Drug: Rapidly dissolving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapidly dissolving levetiracetam minitablets (1000 mg)
Study: 22344554
Drug: Rapidly dissolving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapidly dissolving levetiracetam minitablets (1500 mg)
Study: 22344554
Drug: Single-unit film-coated
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-unit film-coated originator tablets (1000 mg)
Study: 22344554
Drug: Single-unit film-coated
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-unit film-coated originator tablets (1500 mg)
Study: 21500238
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy for Binge Eating Disorder (DBT‐BED)
Study: 20171332
Drug: Active Comparison
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparison Group Therapy (ACGT)
Study: 16895621
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen 15 mg kg‐1
Study: 16895621
Drug: Intramuscular meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meperidine 1 mg kg‐1
Study: 10522990
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg aldosterone
Study: 10522990
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg aldosterone
Study: 7747707
Drug: TAE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAE plus UFT (tegafur 200 mg and uracil 448 mg per day)
Study: 1674230
Drug: roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine acetate hydrochloride 75 mg at 9 PM
Study: 27824913
Drug: Anti-epileptic drugs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-epileptic drugs (AEDs)
Study: 19922572
Drug: Intranasal naloxone
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal naloxone (2 mg)
Study: 30867551
Drug: Intranasal naloxone
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal naloxone (2 mg and 4 mg)
Study: 28083711
Drug: Imatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib treatment (first-line)
Study: 21300377
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of an antipsychotic and an antidepressant
Study: 19342609
Drug: Peripheral parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral parenteral nutrition with thiamine (n=8)
Study: 19342609
Drug: Peripheral parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral parenteral nutrition without thiamine (n=7)
Study: 10485530
Drug: Ketorolac ophthalmic
Normalized name: ketorolac ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac ophthalmic drops 0.5% prescribed four times a day for at least 3 months
Study: 8934482
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (2 ml containing 40 mg of triamcinolone acetonide + 4 ml of 1% lidocaine without epinephrine)
Study: 8934482
Drug: Control (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (6 ml of 1% lidocaine without epinephrine)
Study: 6352169
Drug: Antabuse (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antabuse (50 to 200 mg daily for 6 weeks)
Study: 24735962
Drug: FC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FC plus subcutaneous alemtuzumab 30 mg on day 1 (FCA)
Study: 9696518
Drug: Lightbox treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lightbox treatment with 1500-2500 lux white light for 2 h in the morning for 6 days (n=34)
Study: 9696518
Drug: Dawn simulation
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dawn simulation treatment in their homes, with 60 or 90 min of light augmentation time to 100-300 lux for 2 weeks (n=27)
Study: 3207528
Drug: Low-dose fentanyl
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fentanyl anaesthesia
Study: 29158726
Drug: Mineral glycinate
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mineral glycinate complexes + 2 CENs (daily dose: 36 mg iron, 15 mg zinc, 2 mg copper, 2 g carnitine, 400 mg phosphatidylserine)
Study: 29158726
Drug: Mineral glycinate
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mineral glycinate complexes + 2 CENs (1 g carnitine)
Study: 24179297
Drug: Social Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Cognitive Therapy (SCT)